Home Companies Catalysts Deep Dives
Iclusig ponatinib APPROVED
Drug Profile
ModalitySmall molecule
RoutePO
Therapy AreaOncology
Launch2012-12-14
US LOE2027-01-01
Peak Sales Est$600M
Formulations[{"id":"iclusig-po","route":"PO","setting":"OUTPATIENT","frequency":"Once daily","is_primary":true}]
Companies
TAK (ORIGINATOR)100%
Mechanism: BCR-ABL inhibitor (pan)
Expert: Third-generation TKI active against native BCR-ABL and all single-mutant forms including T315I.
Everyday: Blocks multiple forms of a protein that drives certain blood cancers.
Targets: ["BCR-ABL"]
Revenue History
PeriodRevenue ($M)
2024$480M
Programs (1)
IndicationStageKey StudyRegional Status
CML T315IAPPROVEDPACE[{"stage":"APPROVED","region":"US","approval_date":"2012-12-14"}]
Notes
Only TKI active against T315I mutation in CML/ALL. Cardiovascular risk requires monitoring. Niche but durable.
Data from Supabase · Updated 2026-03-24